Lisata Therapeutics (LSTA) Investor Presentation - Slideshow

2nd line Esophageal SCC (after failure on first line IO) Sponsor/Partner Qilu Pharmaceutical (funds all development in China) Phase 2b, double-blind, placebo-controlled, randomized study evaluating LSTA1 + SoC (Qilu-produced nab-paclitaxel and gemcitabine) vs. placebo + SoC Objective response rate, progression free survival, overall survival Safety 47 • Sponsor/Partner: Qilu Pharmaceutical (funds all development in China) Gemcitabine + Qilu produced nab-paclitaxel + LSTA1 3.2 mg/kg Disease Progression MORPH ...